Ionis Pharmaceuticals develops RNA-targeted medicines using antisense oligonucleotide technology it helped pioneer. Its portfolio and pipeline address rare and serious genetic and other diseases, often through partnerships with larger drugmakers. The platform aims to silence or modulate disease-related genes at the RNA level rather than with traditional small-molecule or protein drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 131.6 | — | -146.9 | — |
| Q2 2025 | 452.1 | — | 123.5 | — |
| Q3 2025 | 156.7 | — | -128.6 | — |
| Q4 2025 | 203.3 | — | -229.4 | — |
| Q1 2026 | 246.1 | 87% | -92.5 | — |
| Q2 2026 | 267.9 | -40.7% | -114.7 | -192.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Celsius Holdings, Inc. (CELH), Pilgrim's Pride Corporation (PPC), Valley National Bancorp (VLY), Zillow Group, Inc. (Z), Alkermes plc (ALKS), StoneX Group Inc. (SNEX)